Rush A J, Weissenburger J, Vasavada N, Orsulak P J, Fairchild C J
Mental Health Clinical Research Center, University of Texas, Southwestern Medical Center, Dallas 75235.
J Clin Psychopharmacol. 1988 Dec;8(6):421-5.
Thirty-five (35) inpatients with nonpsychotic major depression were randomly assigned to either amitriptyline or nortriptyline on a double-blind basis, following a 4- to 10-day placebo run-in period. Thirty-two patients completed at least 3 weeks of active medication. The 1.0-mg dexamethasone suppression test (DST) was performed before treatment. Twelve of 32 patients were DST nonsuppressors. Both medications were equally effective. Pretreatment DST status failed to predict overall response to both medications combined. DST status also did not predict differential medication response. These data argue, along with several other studies, that pretreatment DST status may be of limited value in selecting a particular tricyclic antidepressant compound.
35名非精神病性重度抑郁症住院患者在经过4至10天的安慰剂导入期后，被双盲随机分配至接受阿米替林或去甲替林治疗。32名患者完成了至少3周的活性药物治疗。治疗前进行了1.0毫克地塞米松抑制试验（DST）。32名患者中有12名DST非抑制者。两种药物疗效相当。治疗前DST状态无法预测联合使用两种药物后的总体反应。DST状态也无法预测药物的差异反应。这些数据与其他几项研究一致，表明治疗前DST状态在选择特定三环类抗抑郁化合物时可能价值有限。
